Evidence map›Paper›PMID 32002634›Full record

ReviewClinical research in cardiology : official journal of the German Cardiac Society2020

Natriuretic peptides: biomarkers for atrial fibrillation management.

Alireza Sepehri Shamloo, Andreas Bollmann, Nikolaos Dagres, Gerhard Hindricks, Arash Arya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical research in cardiology : official journal of the German Cardiac Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alireza Sepehri ShamlooDepartment of Electrophysiology, Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany. Sepehria871@gmail.com.ORCID http://orcid.org/0000-0002-4894-8664
Andreas BollmannDepartment of Electrophysiology, Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany.
Nikolaos DagresDepartment of Electrophysiology, Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany.
Gerhard HindricksDepartment of Electrophysiology, Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany.
Arash AryaDepartment of Electrophysiology, Leipzig Heart Institute, Heart Center Leipzig at University of Leipzig, Strümpellstrasse 39, 04289, Leipzig, Germany.
Leipzig Heart Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical practice, atrial fibrillation (AF) is known as the most common sustained arrhythmia. Therefore, identification of individuals at risk of AF development/recurrence or its associated complications has emerged as a hot topic in the field of cardiology. Recently, several biomarkers have been introduced to predict AF and its consequences; however, use of biomarkers in AF management has not been highly recommended by guidelines yet. While utilization of natriuretic peptides (NPs) including brain (B-type) NPs (BNPs) in heart failure management has been well established, their use in relation to AF has not been fully understood. Accordingly, this review article aimed at presenting an overview of the role of NPs in predicting AF development/recurrence as well as its complications and making suggestions for their use in management of patients with AF in clinical settings.

Indexed as

Disease ManagementAtrial FibrillationBiomarkersHumansNatriuretic PeptidesBiomarkersNatriuretic PeptidesAtrial fibrillationBiomarkerBNPB-Type natriuretic peptideNatriuretic peptideNT-ProBNP

Identifiers

PMID32002634
OpenAlexW3003508135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.